Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells

被引:176
作者
Barbara, A
Delannoy, P
Denis, BG
Marie, PJ
机构
[1] Lariboisiere Hosp, CNRS, INSERM U349, Paris, France
[2] Elemental Res, N Vancouver, BC, Canada
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2004年 / 53卷 / 04期
关键词
D O I
10.1016/j.metabol.2003.10.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is growing evidence that strontium ranelate (SR; S12911-2, PROTELOS; Institut de Recherches Internationales Servier, Courbevoie, France), a compound containing 2 atoms of stable strontium (Sr), influences bone cells and bone metabolism in vitro and in vivo. We previously reported that SR increases bone mass in rats and mice by stimulating bone formation and inhibiting bone resorption. We also showed that short-term treatment with SIR enhances osteoblastic cell recruitment and function in short-term rat calvaria cultures. Because Sr incorporates into the bone matrix, it was of interest to determine whether SR may affect matrix mineralization in long-term culture. To this goal, osteogenic mouse calvaria-derived MC3T3-E1 osteoblastic cells were cultured for up to 14 days in the presence of ascorbic acid and phosphate to induce matrix formation and mineralization. Matrix formation was determined by incorporation of tritiated proline during collagen synthesis. Matrix mineralization was quantified by measuring the number and surface of mineralized nodules using a digital image analyzer. In this model, 1,25(OH)2 vitamin D (11 nmol/L) used as internal control, increased alkaline phosphatase (ALP) activity, an early osteoblast marker, on days 4, 10, and 14 of culture. Treatment with SR (11 mmol/L Sr2+) increased ALP activity at days 4 and 14 of culture. SIR also increased collagen synthesis at days 4 and 10 of culture. In contrast, 1,25(OH)2 vitamin D (1 nmol/L) inhibited collagen synthesis at 4 to 14 days of culture. Long-term treatment with SR (0.1 to 1 mmol/L Sr2+) dose dependently increased Sr concentration into the calcified nodules, but did not alter matrix mineralization in long-term culture, as shown by the ratio of the surface of mineralized nodules to the number of mineralized nodules on day 14 of culture. These results show that long-term treatment with SIR increases collagenous matrix formation by MC3T3-E1 osteoblasts without inducing deleterious effect on matrix mineralization. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:532 / 537
页数:6
相关论文
共 46 条
[1]   In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation [J].
Baron, R ;
Tsouderos, Y .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 450 (01) :11-17
[2]  
Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097-4644(19980201)68:2<269::AID-JCB13>3.0.CO
[3]  
2-A
[4]  
Boivin G, 1996, J BONE MINER RES, V11, P1302
[5]   Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis) [J].
Buehler, J ;
Chappuis, P ;
Saffar, JL ;
Tsouderos, Y ;
Vignery, A .
BONE, 2001, 29 (02) :176-179
[6]   NORMAL MATURATIONAL CHANGES IN BONE-MATRIX, MINERAL, AND CRYSTAL SIZE IN THE RAT [J].
BURNELL, JM ;
TEUBNER, EJ ;
MILLER, AG .
CALCIFIED TISSUE INTERNATIONAL, 1980, 31 (01) :13-19
[7]   The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro [J].
Canalis, E ;
Hott, M ;
Deloffre, P ;
Tsouderos, Y ;
Marie, PJ .
BONE, 1996, 18 (06) :517-523
[8]   Increased bone strontium levels in hemodialysis patients with osteomalacia [J].
D'Haese, PC ;
Schrooten, I ;
Goodman, WG ;
Cabrera, WE ;
Lamberts, LV ;
Elseviers, MM ;
Couttenye, MM ;
De Broe, ME .
KIDNEY INTERNATIONAL, 2000, 57 (03) :1107-1114
[9]   Incorporation and distribution of strontium in bone [J].
Dahl, SG ;
Allain, P ;
Marie, PJ ;
Mauras, Y ;
Boivin, G ;
Ammann, P ;
Tsouderos, Y ;
Delmas, PD ;
Christiansen, C .
BONE, 2001, 28 (04) :446-453
[10]   Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice [J].
Delannoy, P ;
Bazot, D ;
Marie, PJ .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (07) :906-911